baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UBS Knock-Out IDP/ DE000UM3GCG3 /

2024-07-29 9:54:51 PM	Chg.+0.030	Bid-	Ask-	Underlying	Strike price	Expiration date	Option type
0.350EUR	+9.38%	- Bid Size: -	- Ask Size: -	BIOGEN INC. DL -,000...	178.2091 -	2078-12-31	Call

GlobeNewswire 06-28 “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

GlobeNewswire 06-24 TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

GlobeNewswire 06-10 FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...

GlobeNewswire 06-03 Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...

GlobeNewswire 05-30 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...

GlobeNewswire 05-22 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...

GlobeNewswire 05-21 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

GlobeNewswire 05-16 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...

GlobeNewswire 05-15 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...

GlobeNewswire 05-02 Biogen Reports Progress on Corporate Responsibility Priorities

GlobeNewswire 04-25 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...

TeleTrader 04-24 Biogen posts Q1 revenue of $2.3 billion

GlobeNewswire 04-23 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...

GlobeNewswire 04-02 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

GlobeNewswire 03-06 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...

GlobeNewswire 03-04 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...

GlobeNewswire 02-23 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...

TeleTrader 02-13 Biogen's Q4 revenue falls 6% to $2.4 billion

GlobeNewswire 02-12 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...

TeleTrader 02-12 Earnings preview: Robinhood, Coinbase and more

GlobeNewswire 02-08 Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

GlobeNewswire 01-04 Stran & Company Appoints Ian Thomas Wall as Chief Information Officer

GlobeNewswire 2023-12-19 Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...

GlobeNewswire 2023-12-15 CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...

GlobeNewswire 2023-12-14 ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is...

UBS Knock-Out IDP/ DE000UM3GCG3 /

If you wish to receive reply to your feedback, please provide your email address.